Gilead has just released the text of its hepatitis C license.  Although there has been some praise for Gilead offering expanded generic access in 91 countries where over 100 million people living with hepatitis C live, there has also been mounting criticism over its exclusion of 51 middle-income countries with 49 million infected. This paper … Continue reading Gilead’s Hepatitis C Medicines License – Troubling Territorial Exclusions, Illusory Exceptions, and Tiered Pricing Policy Fracture Global Access